WHERE ARE YOU?

Concept Pre-Sub Submission prep Newly cleared Raising Postmarket & security

THE TAPE

Elucid raises $55M Series D with FFR-CT 510(k) under FDA review Enovis to buy eCential Robotics for 155 million euros FDA authorizes Vitestro's Aletta, the first autonomous blood-drawing robot, five months after a $70M Series B Renata Medical raises $25M Series D to scale the Minima pediatric stent FDA opens a docket on how to regulate generative AI devices FDA clears Jupiter Endovascular's Vertex thrombectomy system for pulmonary embolism in 89 days FDA clears Wandercraft's Eve, the first self-balancing exoskeleton for home use Meduloc raises $4M Series B to start alpha launch of its nitinol fracture implant FDA sets FY2027 device user fees: $28,653 for a 510(k), $13,785 to register Elucid raises $55M Series D with FFR-CT 510(k) under FDA review Enovis to buy eCential Robotics for 155 million euros FDA authorizes Vitestro's Aletta, the first autonomous blood-drawing robot, five months after a $70M Series B Renata Medical raises $25M Series D to scale the Minima pediatric stent FDA opens a docket on how to regulate generative AI devices FDA clears Jupiter Endovascular's Vertex thrombectomy system for pulmonary embolism in 89 days FDA clears Wandercraft's Eve, the first self-balancing exoskeleton for home use Meduloc raises $4M Series B to start alpha launch of its nitinol fracture implant FDA sets FY2027 device user fees: $28,653 for a 510(k), $13,785 to register

The Tracker / October 2025 / K251851

510(k) cleared

DIASAFEplusUS (F00013010)

Fresenius Medical Care Renal Therapies Group, LLC · Oct 9, 2025 · K251851

FDA cleared the DIASAFEplusUS (F00013010) from Fresenius Medical Care Renal Therapies Group, LLC on Oct 9, 2025 under K251851, a traditional 510(k). The device falls under product code FIP, Subsystem, Water Purification, regulated at 21 CFR 876.5665 as a Class 2 device. The review panel was Gastroenterology, Urology.

FDA logged the submission as received on Jun 16, 2025. The decision came 115 days later, longer than the 90 FDA-day review goal, which usually means at least one additional information request.

Fresenius Medical Care Renal Therapies Group, LLC has 8 other decisions in the tracker over the last 12 months: K261267 (Careflux H60;Careflux H70;Careflux V500), K252377 (NxStage System One with NxView), K252459 (multiFlux 130 (F00013123); multiFlux 160 (F00013124)), K253462 (NaturaLyte® Dry Bicarbonate Concentrate (08-4112-2)).

Questions & Answers

What did FDA clear under K251851?

K251851 is the FDA 510(k) for DIASAFEplusUS (F00013010), submitted by Fresenius Medical Care Renal Therapies Group, LLC. FDA's decision date was Oct 9, 2025, under product code FIP (Subsystem, Water Purification).

Who makes the DIASAFEplusUS (F00013010)?

Fresenius Medical Care Renal Therapies Group, LLC, based in Waltham, MA, is the applicant of record for K251851.

How long did the K251851 review take?

FDA received the submission on Jun 16, 2025 and issued its decision on Oct 9, 2025, 115 days later.

← All decisions in October 2025